SPC changes
Vfend
The summary of product characteristics for Vfend (voriconazole; Pfizer)
50mg and 200mg film-coated tablets, Vfend 200mg powder for solution for
infusion and Vfend 40mg/ml powder for oral suspension has been updated.
It now states that coadministration with low dose ritonavir (100mg twice
daily) should be avoided unless an assessment of the benefit and risk
justifies the use of voriconazole. See SPC.
Zomacton
The summary of product characteristics for Zomacton (somatropin; Ferring)
injection 4mg now states that Zomacton contains 9mg/ml benzyl alcohol,
that it must not be given to premature babies or neonates and that
it may cause toxic reactions and anaphylactoid reactions in infants
and children up to three years old. See SPC.
Back to Top
|